Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 75 years old
- You have been diagnosed with liver cancer (hepatocellular carcinoma), confirmed either by a tissue sample or by standard medical imaging and clinical assessment
- Your liver cancer is classified as an early or intermediate stage (known as BCLC stage A or B) (confirm with trial site)
- You have already received a treatment called TACE (a procedure that delivers chemotherapy directly to the liver tumor through its blood supply)
- You are scheduled to have a special type of CT scan (contrast-enhanced spectral CT) between 4 and 8 weeks after your TACE treatment
- After that CT scan, you will either have surgery to remove part of your liver within 1 week, OR you will have another imaging test (a type of X-ray using dye, or an MRI scan) within 1 week
- You are willing and able to give your informed consent to take part
Who may not be able to join:
- You have a medical reason why you cannot safely receive the dye/contrast used in CT or MRI scans
- You have a cancer elsewhere in your body outside the liver
- Your scan images are not clear enough, or your medical records are incomplete
- You are in the non-surgical group but are unable to attend regular follow-up CT or MRI appointments
- You have chosen to withdraw from the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 86 13852914095
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Diagnostic accuracy of spectral CT in identifying nonviable HCC lesions.; Diagnostic Performance of Spectral CT for Residual Viable Hepatocellular Carcinoma After TACE.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.